News
DoP further extends timeline to apply for support under PLI scheme for bulk drugs: Gireesh Babu, New Delhi Wednesday, July 9, 2025, 08:00 Hrs [IST] The Department of Pharmaceutica ...
Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback